Navigation Links
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Date:11/5/2008

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended September 30, 2008. Revenues for the third quarter of 2008 were $0.8 million, compared with revenues of $0.4 million for the third quarter of 2007. The net loss for the third quarter of 2008 was $9.8 million or $0.24 per share, compared with $9.2 million or $0.24 per share for the third quarter of 2007.

Revenues for the first nine months of 2008 were $5.3 million, compared with revenues of $4.7 million for the first nine months of 2007. The net loss for the first nine months of 2008 was $27.9 million, or $0.70 per share, compared with a net loss of $27.0 million, or $0.69 per share, for the first nine months of 2007.

Vical had cash and investments of $49 million at September 30, 2008. The company's third quarter 2008 financial results were consistent with its projection for a full year net loss of $32 million to $37 million and a net cash burn of $27 million to $32 million.

CMV Vaccine

During the third quarter, Vical achieved the milestone of enrolling the 80th stem cell transplant recipient in the company's Phase 2 cytomegalovirus (CMV) vaccine trial. The company expects to announce during the fourth quarter the results of an interim analysis in this trial on those subjects who were enrolled by the end of March.

H5N1 Pandemic Influenza Vaccines

Vical and AnGes MG, Inc., signed a non-binding Letter of Intent in October indicating their mutual interest in licensing the development and marketing rights for Vical's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines in Japan to AnGes. Vical reported in July that the company's pandemic influenza DNA vaccines achieved potentially protective levels of antibody responses (H5 hemagglutination inhibition, or HI, titers of at least 40 and at least a four-fold increase from baseline) in at least 50% and up to 67% of evaluable subjects in t
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
2. Vical to Present at Upcoming Investor Conferences
3. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
4. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
5. Vical to Present at UBS Global Life Sciences Conference
6. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
7. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
8. Vical to Present at Upcoming Investor Conferences
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
11. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... , SUNNYVALE, Calif., Oct. 13 Cepheid (Nasdaq: CPHD ... its third quarter ended September 30, 2009, on Wednesday, October ... company will host a management presentation at 2 p.m. Pacific ... To access the live webcast, please visit Cepheid,s website ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today that it ... from the National Institute of Allergy and Infectious Diseases (NIAID) ... from the NIAID is to support a segment of the ... particle-based vaccine. RSV is the most commonly identified cause ...
... CAMBRIDGE, Mass., Oct. 13 Cequent Pharmaceuticals, a pioneer ... treatments to prevent and treat human disease, announced that ... Cequent,s planned launch of its clinical program and highlight ... for 3 p.m. on Tuesday, October 27, 2009, at ...
Cached Biology Technology:Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 3Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27 2
(Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
(Date:9/1/2014)... the U.S. undergoes a battery of tests designed to ... Thousands of children born in the developing world, however, ... the disease each year. , A.J. Kumar hopes ... those deaths. , A Post-Doctoral Fellow in Chemistry ... Whitesides, the Woodford L. and Ann A. Flowers University ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... school students and teachers sounds like a witches brew for an ... Instead, these are the components that comprise the ... developed by researchers at Washington University in St. Louis and a ... Lars Angenent, Ph.D., assistant professor of ...
... a pair of proteins that work in concert to restart ... dormancy. The Hawley Lab has described the dual ... that awakens the long-dormant egg, allowing for production of a ... Dec. 4, 2007 issue of PLoS Biology. The ...
... may have begun in the protected spaces inside of layers ... new hypothesis. The hypothesis was developed by Helen Hansma, ... and a program director at the National Science Foundation. Hansma ... Dec. 4, at the annual meeting of the American Society ...
Cached Biology News:Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2New hypothesis for origin of life proposed 2
... Blot Processing Standard Tray (3 ... for gel staining and blot processing.Automated ... gels for proteins and nucleic acid ... detection and chromogenic detection.Programmable control of ...
... Dithiothreitol, 1 g. High quality ... sample preparation that give consistent ... cells and tissues.Clean up samples ... volumes. Accurately quantitate protein for ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
Biology Products: